Press Releases

Jeffrey L. Saver to Chair Astrocyte Pharmaceuticals’ Clinical Advisory Board

Cambridge, MA, December 11, 2018 – Astrocyte Pharmaceuticals Inc., a privately held pharmaceutical company, today announced that Jeffrey L. Saver, M.D., has joined the company’s Scientific Advisory Board and will chair the company’s Clinical Advisory Board. Astrocyte Pharmaceuticals is developing small molecule therapeutics for the treatment of brain injuries, including patients who have suffered a …

Jeffrey L. Saver to Chair Astrocyte Pharmaceuticals’ Clinical Advisory Board Read More »

Astrocyte Pharmaceuticals Awarded $3M NIH Small Business Grant to Advance TBI and Concussion Therapeutic

Cambridge, MA, September 19, 2018 – Astrocyte Pharmaceuticals Inc., a privately held pharmaceutical company, announced today that it has been awarded a $3 million Phase 2 Small Business Innovation Research (SBIR) Grant from the National Institute Of Neurological Disorders And Stroke (NINDS) of the National Institutes of Health (NIH).  The grant provides funding to advance …

Astrocyte Pharmaceuticals Awarded $3M NIH Small Business Grant to Advance TBI and Concussion Therapeutic Read More »

Astrocyte Pharmaceuticals Awarded Alzheimer’s Disease Research Grant

Cambridge, MA, September 18, 2018 – Astrocyte Pharmaceuticals, Inc., a privately held pharmaceutical company, announced today that it has been awarded $287k Phase 1 Small Business Technology Transfer (STTR) Grant from the National Institutes of Health’s (NIH) National Institute On Aging (NIA).  The grant provides funding to further evaluate and advance its promising neuroprotectant drug …

Astrocyte Pharmaceuticals Awarded Alzheimer’s Disease Research Grant Read More »

Astrocyte Pharmaceuticals Completes $2.3M Pre-A Financing Round

Cambridge, MA, June 6, 2018 – Astrocyte Pharmaceuticals Inc. announced today that it has completed a Pre-A financing round that raised over $2.3M.  The company is advancing several small molecule neuroprotective therapeutics for the treatment of stroke, traumatic brain injury (TBI) or concussion, and neurodegenerative disease. The Pre-A round was led by Kaitai Capital, and …

Astrocyte Pharmaceuticals Completes $2.3M Pre-A Financing Round Read More »

Astrocyte Pharmaceuticals Completes $2.4M Seed Financing Round

Cambridge, MA, July 17, 2017 – Astrocyte Pharmaceuticals Inc. announced today that it has completed its seed financing round raising over $2.4M.  The company is developing novel small molecule drugs that limit neuronal damage in patients that have suffered a stroke, traumatic brain injury (TBI) or concussion. As previously announced, the seed financing round was …

Astrocyte Pharmaceuticals Completes $2.4M Seed Financing Round Read More »

Astrocyte Pharmaceuticals Raises Over $1.3M in Seed Financing Round

Cambridge, MA, March 24, 2017 – Astrocyte Pharmaceuticals Inc., a CNS therapeutics startup, announced today that it has raised approximately $1.36M in a seed financing round.  The company is developing novel small molecule drugs that limit neuronal damage in patients that have suffered a stroke, traumatic brain injury (TBI) or concussion. The seed financing round …

Astrocyte Pharmaceuticals Raises Over $1.3M in Seed Financing Round Read More »

Former Army TBI Research Leader Col. Dallas Hack Joins Astrocyte Pharmaceuticals’ Scientific Advisory Board

Cambridge, MA, December 19, 2016 – Astrocyte Pharmaceuticals Inc., a privately held pharmaceutical company, announced today that Colonel (retired) Dallas C. Hack, MD, MPH has joined the company’s Scientific Advisory Board. Astrocyte Pharmaceuticals is developing novel small molecule therapeutics for acute administration to patients who have suffered a stroke, traumatic brain injury (TBI) or concussion. …

Former Army TBI Research Leader Col. Dallas Hack Joins Astrocyte Pharmaceuticals’ Scientific Advisory Board Read More »

Leading Emergency Clinician David W. Wright Joins Astrocyte Pharmaceuticals’ Scientific Advisory Board

Cambridge, MA, October 19, 2015 – Astrocyte Pharmaceuticals Inc., a privately held pharmaceutical company, announced today that David W. Wright, M.D., has joined the company’s Scientific Advisory Board. Astrocyte Pharmaceuticals is developing breakthrough small molecule therapeutics for acute administration to patients who have suffered a traumatic brain injury (TBI), concussion or stroke. “Dr. Wright is …

Leading Emergency Clinician David W. Wright Joins Astrocyte Pharmaceuticals’ Scientific Advisory Board Read More »

Astrocyte Pharmaceuticals Awarded NIH Small Business Grant to Advance TBI and Concussion Therapeutic

Cambridge, MA, September 21, 2015 – Astrocyte Pharmaceuticals Inc., a privately held pharmaceutical company, announced today that it has been awarded a Phase 1 Small Business Technology Transfer (STTR) Grant from the National Institutes of Health (NIH) to further evaluate and advance its promising drug candidate for traumatic brain injuries (TBI) and concussions. Astrocyte Pharmaceuticals …

Astrocyte Pharmaceuticals Awarded NIH Small Business Grant to Advance TBI and Concussion Therapeutic Read More »

Dr. Susan S. Margulies Joins Astrocyte Pharmaceuticals’ Scientific Advisory Board

Cambridge, MA, July 16, 2015 – Astrocyte Pharmaceuticals Inc., a privately held pharmaceutical company, announced today that Susan S. Margulies, Ph.D. has joined the company’s Scientific Advisory Board. Astrocyte Pharmaceuticals is developing breakthrough small molecule therapeutics for acute administration to patients who have suffered a traumatic brain injury (TBI), concussion or stroke. “Dr. Margulies is …

Dr. Susan S. Margulies Joins Astrocyte Pharmaceuticals’ Scientific Advisory Board Read More »